CUE BIOPHARMA INC
Cue Biopharma Inc is an immuno-oncology biotechnology company focusing on specialized biologic drug development platforms
Stock Performance Snapshot
Analyst Rating
Analysts strongly recommend buying CUE Biopharma's stock, predicting it could rise to $9.
Financial Health
CUE Biopharma is generating modest revenue and cash flow, with a stable book value per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Trial Readouts Matter
Clinical data are primary value drivers for Cue; positive or negative results can move the stock sharply, though outcomes are uncertain.
Binary Clinical Risk
As an early-stage biotech, Cue faces high binary risk around trial outcomes and regulatory decisions; potential reward comes with elevated volatility.
Partnerships & Funding
Licensing deals or successful financing can de‑risk development and extend runway, but funding needs may also dilute shareholders.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals develops treatments for diseases including cystic fibrosis and cancer.
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals is a leading biotechnology company that develops and manufactures innovative medicines for serious medical conditions.
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics based on RNA interference (RNAi).
